U.S. – Page 2 – Talk Bio

‘Now is not the time to retreat’: BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

3 months ago talkbio0Tagged Drug Industry, Health Care Reform, Home environment, Manufacturing, Myers, pharmaceutical manufacturing, pharmaceutical tariffs, squibb, Trump tariffs, U.S.

Bristol Myers Squibb, Trump tariffs, pharmaceutical manufacturing, domestic investment, pharmaceutical industry, US manufacturing, healthcare reform, pharmaceutical tariffs

Gilead, ‘closely attuned to’ potential US policy shifts, stands by long-acting PrEP launch

3 months ago talkbio0Tagged Gilead, HIV Prevention, launch, Lenacapavir, long-acting, Pre-Exposure Prophylaxis, U.S., United States Food and Drug Administration

Lenacapavir, Pre-Exposure Prophylaxis, United States Food and Drug Administration, launch, HIV prevention, long-acting, U.S., Gilead

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

3 months ago talkbio0Tagged CEOs, EU, Financial cost, Investments, Market, nations, Novartis, Parity, Pharma, Prices, sanofi, Transplant Registry Unified Management Program, U.S.

EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

4 months ago talkbio0Tagged Administration occupational activities, Administrative Procedure Act, appeal, CHARGE Syndrome, federal judge, Health Policy, Indirect, injunction, Legal, Medical Research activity, NIH Mouse, Permanent, research, Transplant Registry Unified Management Program, U.S., United States

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

4 months ago talkbio0Tagged alpha 1-antitrypsin, Biopharma trade war, Drug Industry, Drug packaging industry, Generic Drugs, Impact food supplement, lobbying, Manufacturing, Market, onshoring, Pharmaceutical Supply Chain, pharmaceutical tariffs, Supply chain disruption, Trump tariffs, U.S., United States

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying